GlassScriptPhysician profile
James R Duncan
NPI 1922460500
$6,835.25
in general payments reported to CMS, 2019-2025
30 companies · $1,957 in 2025
The $1,957 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $192 · 2021: $353 · 2022: $1,091 · 2023: $1,344 · 2024: $1,590 · 2025: $1,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,638 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,638.30 |
| Education | $252.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,532.75 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $490.56 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $464.99 | 2023-2025 | Tremfya |
| Pfizer INC. | $407.31 | 2022-2025 | |
| Genzyme Corporation | $353.11 | 2022-2025 | |
| Incyte Corporation | $345.92 | 2021-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $341.84 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $327.91 | 2022-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $303.92 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $260.28 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $235.05 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $209.18 | 2023-2025 | Sotyktu |
| Amgen INC. | $197.62 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $166.61 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $159.83 | 2021-2025 | Nemluvio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $145.10 | 2021-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $121.86 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $118.26 | 2021-2025 | Cabtreo, Arazlo |
| Novartis Pharmaceuticals Corporation | $117.84 | 2023-2025 | |
| Leo Pharma INC. | $106.16 | 2022-2023 | Adbry |
| Allergan, INC. | $97.33 | 2019 | |
| Almirall LLC | $88.26 | 2022-2025 | Seysara, Klisyri |
| Organogenesis INC. | $76.44 | 2023-2025 | Puraply, Affinity |
| Organon LLC | $65.40 | 2025 | |
| Verrica Pharmaceuticals INC. | $19.99 | 2023 | Ycanth |
| Medimetriks Pharmaceuticals, INC. | $19.40 | 2022 | |
| Fresenius Kabi USA, LLC | $18.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.66 | 2025 | Spevigo |
| Stemline Therapeutics INC. | $14.00 | 2021 | |
| Ani Pharmaceuticals, INC. | $13.67 | 2023 | Veregen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.